3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-4-methoxybenzoic acid | 1424337-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-4-methoxybenzoic acid
• 英文别名: 3-[4-(1,3-Dioxoisoindol-2-yl)butoxy]-4-methoxybenzoic acid；3-[4-(1,3-dioxoisoindol-2-yl)butoxy]-4-methoxybenzoic acid
• CAS: 1424337-21-2
• 化学式: C₂₀H₁₉NO₆
• 分子量: 369.374
• InChiKey: UVSDJAMBSKPBJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-4-methoxybenzoic acid 在 盐酸 、 氟化铵 、 氯化亚砜 、 sodium hydride 、 一水合肼 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 93.75h， 生成 N-(3,5-dichloropyridin-4-yl)-3-[4-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]butoxy]-4-methoxybenzamide
  参考文献：
  名称：

  Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

  摘要：

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.058
• 作为产物：
  描述：

  N-(4-溴丁基)邻苯二甲酰亚胺 在 sodium chlorite 、 sodium dihydrogenphosphate 、 双氧水 、 potassium carbonate 、 potassium iodide 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 43.5h， 生成 3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)-4-methoxybenzoic acid
  参考文献：
  名称：

  Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

  摘要：

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.058

文献信息

• Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD
  作者：Anqiu Liu、Ling Huang、Zhiren Wang、Zonghua Luo、Fei Mao、Wenjun Shan、Jiaxing Xie、Kefang Lai、Xingshu Li

  DOI：10.1016/j.bmcl.2012.11.058

  日期：2013.3

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.